Brought to you by 
Arena Pharmaceuticals nets $50mm through public offering
04 Aug 2009
Executive Summary
Arena Pharmaceuticals (cardiovascular, neurology, inflammation, and metabolic therapeutics) has netted $50mm through the public sale of 12.5mm common shares at $4.17 each. Just last month the company accepted a $100mm loan from Deerfield Management, one of its largest shareholders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arena Pharmaceuticals nets $50mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice